This article is available to subscribers. Subscribe now. Already have an account? Sign in

Medical IntelligenceFree PreviewArchive

Nonenzymatically Galactosylated Serum Albumin in a Galactosemic Infant

List of authors.
  • Joseph C. Urbanowski, Ph.D.,
  • Menashi A. Cohenford, Ph.D.,
  • Harvey L. Levy, M.D.,
  • John D. Crawford, M.D.,
  • and Joel A. Dain, Ph.D.

Galactosemia is a molecular disease of genetic origin that is characterized by a deficiency of galactose-1-phosphate uridyltransferase.1 , 2 The resulting severe impairment of galactose metabolism has been recognized for over half a century, and the frequency of this disorder is estimated to be one to four in 100,000 births.3 , 4 Generally, the biochemical phenotype includes elevated concentrations of galactose, galactose-1-phosphate, and galactitol in tissue and body fluids.2 In neonates the clinical sequelae consist of vomiting, jaundice, hepatosplenomegaly, and death, and in surviving infants cirrhosis of the liver, mental retardation, and cataracts occur as chronic complications if dietary galactose is not restricted. 2 , 3 , 5 Sepsis . . .

Funding and Disclosures

Supported in part by grants (NS 05104 and NS 05096) from the National Institutes of Health.

Author Affiliations

From the Department of Biochemistry and Biophysics, University of Rhode Island, Kingston; and the Joseph P. Kennedy, Jr., Memorial Laboratories of the Neurology Service and the Children's Service, Massachusetts General Hospital and the departments of Neurology and Pediatrics, Harvard Medical School, Boston. Address reprint requests to Dr. Dain at the Department of Biochemistry and Biophysics, University of Rhode Island, Kingston, RI 02881.

Print Subscriber? Activate your online access.